Biotech Values

[ghmm]

The Actimmune number is a bit disappointing (they tried to explain it a bit) lets see how much the market cares about this.

They (as usually) gave some but not too much detail and wide ranges.

Here is the pertinent 191 info from the PR
-- InterMune expects to complete the currently running Phase 1a study of ITMN-191 in healthy subjects in the first half of 2007.

-- InterMune plans to evaluate ITMN-191 in a Phase 1b randomized, double- blind, placebo controlled, multiple ascending dose study in patients infected with chronic hepatitis C virus. ITMN-191 will be administered to treatment naïve patients for 14 days and the study will include a cohort of non- responder patients. InterMune and its partner Roche expect to announce initial viral kinetic results from the Phase 1b trial in the second half of 2007.


Thats probably it for me for today. I'll try to update the readme sometime after the call hopefully within the next day or two.